Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07224386 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis

Study acronym: BioDigit MG-02
StatusNot Yet Recruiting
PhaseNot specified
SponsorBioSensics
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
BioSensics
8 trials monitored
See 1 trial at risk
Myasthenia Gravis
193 trials monitored
See 7 trials at risk
Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG). Study subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 12 month observational study. Study subjects will be asked to wear multiple wearable sensors to monitor their physical activity and PPG during daily activities. Participants will also complete speech, video, and ePRO and eCOA digital assessments at home and during study visits. The primary objective for this observational study is to measure the correlation of sensor-derived measures of physical activity to MG-specific ratings of MG-ADL, QMG, MGC, and Neuro-QoL Fatigue
Trial Details
NCT Number NCT07224386
Lead Sponsor BioSensics
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS), Massachusetts General Hospital
Conditions
(from sponsor)		 Myasthenia Gravis, Myasthenia Gravis, Generalized
Related terms Myasthenia Gravis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov